Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

Unclear / insufficient evidence Overinterpreted Certainty of evidence: low provisional C-PPI-05

Long-term acid suppression causes hip fractures and pneumonia.

In short: Unclear: observational studies link long-term PPI use with hip fracture and pneumonia, but randomised trials show no clear increase in pneumonia and no fracture excess over three years, so a causal effect is unproven and, if present, small.
Conclusion: Unclear: observational studies link long-term PPI use with hip fracture and pneumonia, but the largest randomised trial did not confirm these risks.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

حمض المعدة ليس عدوّاً يجب قمعه، بل أداة أساسية للهضم وقتل الميكروبات وامتصاص الحديد وفيتامين ب12 والكالسيوم والمغنيزيوم. تثبيطه لفترات طويلة بـ PPIs (أوميبرازول، نكسيم، كونترلوك) أو مثبطات H2 ينقلب على الجسم: مرض كلوي مزمن، فرط نمو بكتيري، عدوى مطثية عسيرة، التهاب رئوي، نقص B12 والمغنيزيوم، كسور ورك، تغيّر الميكروبيوم، وزيادة الوفيات. والأخطر أنّ الجسم يدمن الدواء عبر فرط الإفراز الارتدادي بعد الإيقاف، فيتحوّل الاستخدام القصير إلى اعتماد مزمن.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Long-term acid suppression causes hip fractures and pneumonia.

Origin

Source status
Archive editors
Attribution
Archive editors (eltayebat.com); not verified as Elawady's own words
Origin
https://eltayebat.com/rule/acid-blockers/
Attribution uncertainty
Written by the archive operators; study selection is the archive's, not necessarily Elawady's.
Claimed mechanism

Reduced calcium absorption (bone); loss of acid barrier (pneumonia).

Claimed health effect

Hip fracture; community- and hospital-acquired pneumonia.

Population concerned

Long-term PPI users, older adults.

Geographic restriction by Elawady

none found

Scientific assessment

Unclear / insufficient evidence – The data do not allow an assessment either way.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

PPIs cause hip fractures and pneumonia.

2. What is demonstrably correct?

Associations exist: GPRD nested case-control AOR 1.44 (1.30–1.59) for >1 year of PPI, AOR 2.65 for long-term high dose; meta-analysis of observational studies OR 1.27 (1.11–1.46) for pneumonia.

3. What is wrong or exaggerated?

The archive presents these as proven effects ('raised hip fracture risk 44%'). Case-control and cohort designs cannot exclude confounding (frailty, comorbidity). The pneumonia estimate is very heterogeneous.

4. What remains unclear?

Whether long exposure (>3 years) has a small causal effect on fracture is not settled.

5. Which studies support it?

A-PPI-07, A-PPI-08.

6. Which studies contradict it?

COMPASS (I-PPI-01): no statistically significant difference in fractures or pneumonia with pantoprazole vs placebo.

7. What applies to Germany and Europe?

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

8. What is known about Egypt?

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

9. What practical conclusion is appropriate?

Use the lowest effective dose for an indicated duration; fracture and pneumonia risk alone are not, per AGA guidance, reasons to stop an indicated PPI.

Assessment details

Rationale for certainty of evidence

Observational associations with dose-duration gradients (hip fracture OR 1.44 after >1 year; pneumonia OR 1.27 with high heterogeneity, I² 90.5%); the COMPASS RCT found no significant difference in fractures or pneumonia over 3 years.

Source quality

Correctly cited observational studies; causal language overstated.

Regional transferability

Moderate–high.

Individual exceptions

Older people with other fracture risks may be more affected if an effect exists.

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).

Research question: Does long-term acid suppression cause hip fractures and pneumonia?

Research question in detail (PECO)
Population
Adult PPI users
Intervention or exposure
PPI use
Comparison
Non-use / placebo / H2RA
Geographic scope
universal pharmacology
Outcomes
  • Hip fracture
  • Pneumonia

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Observational associations exist; randomised evidence shows no or at most a small pneumonia increase and no fracture excess over 3 years.

Why some studies weigh more

RCT evidence weighted above observational estimates; the two RCT meta-analyses overlap (counted once).

Is a causal relationship established? Possible, not established Associations could reflect frailty and prodromal effects; RCTs limit the possible size.

Remaining uncertainty

Long-term (>3 years) fracture risk.

Justified conclusion

Unproven as causal.

Why do studies seem to disagree?

SCCS (IRR 1.73) vs RCTs (OR 1.00-1.10): different designs; SCCS susceptible to prescriptions started during pneumonia prodrome.

Does this depend on the country?
General biological effects
Pharmacology of PPIs is the same in Egypt and Europe.
Eating habits
Not decisive.
Origin of the food
Not relevant.
Contaminants
Not relevant (except ranitidine NDMA impurities, C-PPI-08).
National production conditions
Generic products are used in both regions; no evidence of different pharmacological effects.
Legal rules
PPIs are partly available without prescription in Egypt and (small packs, short-term) in the EU; prescribing practices differ.
Actual monitoring data
No Egyptian outcome data identified; one Egypt/Iraq pharmacist survey (I-PPI-120).

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • RCT vs SCCS estimates – RCT upper limits 1.09-1.21 exclude the SCCS IRR 1.73 recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
Pneumonia caused by PPIs
Starting level
high (randomised trials)
Reasons for downgrading
  • inconsistency
  • indirectness
Result
low

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked
  • AGA (American Gastroenterological Association): AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review (Targownik LE et al., Gastroenterology 2022; I-PPI-04) (2022) · Original publication
    Best Practice Advice read verbatim in the PubMed record: regular review and documentation of the indication (BPA 1); trial of de-prescribing for all without a definitive indication (BPA 2); complicated GERD (severe erosive oesophagitis, oesophageal ulcer, peptic stricture) generally not for discontinuation (BPA 4); Barrett's oesophagus, eosinophilic oesophagitis, idiopathic pulmonary fibrosis generally not for de-prescribing (BPA 5); assess upper GI bleeding risk first and do not de-prescribe in high-risk patients (BPA 6-7); warn about transient rebound symptoms (BPA 8); tapering or abrupt stop both possible (BPA 9); decide on indication, not on fear of PPI-associated adverse events (BPA 10). The publisher page could not be fetched (HTTP 403).
Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
Europe PMC26 October 2026TITLE:("proton pump inhibitor*") AND TITLE:(fracture OR pneumonia) AND ("meta-analysis" OR "Mendelian" OR "target trial" OR randomized) AND PUB_YEAR:[2015 TO 2026]both directions14

Open questions

Long-term fracture risk in RCT or target-trial designs.

How deeply was this checked?

7 linked studies: 1 checked in full text (1 of them with a structured risk-of-bias assessment), 6 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: Unclear / insufficient evidence (low)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Unclear / insufficient evidence (low)
    New studies support both sides; balance unchanged.
    New sources: I-PPI-113 I-PPI-114 I-PPI-115

In plain language

Several studies saw more hip fractures and pneumonias among people taking acid blockers for a long time. A large randomised trial did not confirm this over three years. A small effect is possible but not proven.

Studies on this claim

Studies supporting the claim (3)

  • Acid blockers and pneumonia

    Eom CS et al.. CMAJ 2011 · PMID 21173070 · DOI 10.1503/cmaj.092129
    Meta-analysiscited by the Tayebat archiveabstract checked

    PPI users had 27% higher odds of pneumonia in observational studies, with large differences between studies.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Pneumonia risk.

    How was the study done?

    Meta-analysis.

    How many people, animals or samples were studied?

    31 studies.

    What was actually found?

    Possible association.

    How large was the observed effect?

    OR 1.27.

    What do the results mean in everyday life?

    Small possible risk.

    What are the study's limitations?

    Heterogeneity.

    What does it say about Elawady's specific claim?

    Partly supports.

    Do the results apply to Germany and Europe?

    Applicable.

    What can explicitly not be concluded from this study?

    Causation for PPIs.

    Scientific details →

  • PPIs and hip fracture (UK)

    Yang YX et al.. JAMA 2006 · PMID 17190895 · DOI 10.1001/jama.296.24.2947
    Case-control studycited by the Tayebat archiveabstract checked★ key study

    Use for more than a year was associated with 44% higher odds of hip fracture.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Hip fracture association.

    How was the study done?

    Nested case-control in UK GP records.

    How many people, animals or samples were studied?

    148,942 people.

    What was actually found?

    Higher odds with longer, higher-dose use.

    How large was the observed effect?

    AOR 1.44; 2.65.

    What do the results mean in everyday life?

    Possible bone risk with long-term use.

    What are the study's limitations?

    Confounding by frailty.

    What does it say about Elawady's specific claim?

    Partly supports.

    Do the results apply to Germany and Europe?

    UK data.

    What can explicitly not be concluded from this study?

    Causation.

    Scientific details →

  • More pneumonia during periods of PPI use

    Maret-Ouda J et al.. J Gastroenterol 2023 · PMID 37314495 · DOI 10.1007/s00535-023-02007-5
    Otherindependent cross-checkabstract checked

    In Sweden, people had 73% more pneumonia episodes during times they took PPIs than during times they did not.

    Within-person pneumonia IRR 1.73 during PPI use

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test PPIs and pneumonia within the same people.

    How was the study done?

    Self-controlled case series.

    How many people, animals or samples were studied?

    519,152 patients.

    What was actually found?

    IRR 1.73; H2RA 1.08.

    How large was the observed effect?

    1.73 (1.71-1.75).

    What do the results mean in everyday life?

    Pneumonia risk may rise during PPI use.

    What are the study's limitations?

    Possible bias from timing of prescriptions.

    What does it say about Elawady's specific claim?

    Supports the pneumonia association.

    Do the results apply to Germany and Europe?

    Swedish data.

    What can explicitly not be concluded from this study?

    Cannot prove causation.

    Scientific details →

Studies contradicting or limiting the claim (2)

  • Pantoprazole safety in a large randomised trial

    Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
    Randomised controlled trialindependent cross-checkfull text, structured risk-of-bias assessment★ key study

    Over three years, only gut infections were more common with pantoprazole (1.4% vs 1.0%).

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test PPI harms in an RCT.

    How was the study done?

    Placebo-controlled trial.

    How many people, animals or samples were studied?

    17,598 heart/vascular patients.

    What was actually found?

    No excess harm except enteric infections.

    How large was the observed effect?

    OR 1.33 enteric infections.

    What do the results mean in everyday life?

    PPIs are largely safe for 3 years.

    What are the study's limitations?

    3-year duration; specific population.

    What does it say about Elawady's specific claim?

    Contradicts most broad harm claims; supports infection risk.

    Do the results apply to Germany and Europe?

    Applicable.

    What can explicitly not be concluded from this study?

    Very long-term effects.

    Scientific details →

  • Randomised trials: PPIs prevent bleeding without clear infection increase

    Omar MA et al.. J Clin Med 2026 · PMID 41976918 · DOI 10.3390/jcm15072617
    Meta-analysisindependent cross-checkabstract checked★ key study

    In 8 randomised trials with 30,019 people, PPIs reduced serious stomach bleeding and did not significantly increase pneumonia or C. difficile.

    Pneumonia OR 1.00 (0.92-1.09) in RCTs

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Check infection risks of PPIs in RCTs.

    How was the study done?

    Meta-analysis of RCTs.

    How many people, animals or samples were studied?

    30,019 participants.

    What was actually found?

    No significant rise in CDI or pneumonia; less bleeding.

    How large was the observed effect?

    Pneumonia OR 1.00; CDI 1.29; bleeding 0.51.

    What do the results mean in everyday life?

    Short-term PPI prophylaxis is relatively safe when indicated.

    What are the study's limitations?

    Few trials; rare events imprecise.

    What does it say about Elawady's specific claim?

    Limits claims of pneumonia; leaves CDI uncertain.

    Do the results apply to Germany and Europe?

    Applicable.

    What can explicitly not be concluded from this study?

    Cannot exclude small long-term risks.

    Scientific details →

Studies with mixed or unclear results (2)

  • AGA advice on long-term PPIs

    Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031
    Guideline / position statementindependent cross-checkabstract checked

    PPIs are justified for defined indications; risks do not require routine monitoring.

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Risk–benefit guidance.

    How was the study done?

    Expert review.

    What was actually found?

    10 best practice statements.

    What do the results mean in everyday life?

    Use for real indications at lowest dose.

    What are the study's limitations?

    Expert opinion.

    What does it say about Elawady's specific claim?

    Mixed: supports indication-based use.

    Do the results apply to Germany and Europe?

    Applicable.

    Scientific details →

  • Trials hint at a small pneumonia risk at most

    Wu Z et al.. Front Pharmacol 2025 · PMID 41230098 · DOI 10.3389/fphar.2025.1713256
    Meta-analysisindependent cross-checkabstract checked

    Pooling 20 randomised trials, PPI users had a 10% higher pneumonia rate, which was not statistically certain.

    Pneumonia RR 1.10 (0.99-1.21) in RCTs

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Pool RCTs on PPIs and pneumonia.

    How was the study done?

    Meta-analysis.

    How many people, animals or samples were studied?

    29,100 participants.

    What was actually found?

    RR 1.10, borderline.

    How large was the observed effect?

    1.10 (0.99-1.21).

    What do the results mean in everyday life?

    Any pneumonia risk is likely small.

    What are the study's limitations?

    Subgroup multiplicity.

    What does it say about Elawady's specific claim?

    Neither confirms nor excludes a small effect.

    Do the results apply to Germany and Europe?

    European subgroup null.

    What can explicitly not be concluded from this study?

    Cannot prove causation.

    Scientific details →

Regional context

Germany / EU

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

Egypt

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

What applies in my country?

General scientific assessment

Unclear / insufficient evidence Unclear: observational studies link long-term PPI use with hip fracture and pneumonia, but the largest randomised trial did not confirm these risks.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.. Eom CS et al.. CMAJ 2011 · PMID 21173070 · DOI 10.1503/cmaj.092129
  2. Long-term proton pump inhibitor therapy and risk of hip fracture.. Yang YX et al.. JAMA 2006 · PMID 17190895 · DOI 10.1001/jama.296.24.2947
  3. Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study.. Maret-Ouda J et al.. J Gastroenterol 2023 · PMID 37314495 · DOI 10.1007/s00535-023-02007-5
  4. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.. Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
  5. Proton Pump Inhibitor Use for Gastroprotection and Stress Ulcer Prophylaxis Does Not Increase the Risk of Clostridioides difficile Infection or Pneumonia: A Systematic Review and Meta-Analysis of RCTs.. Omar MA et al.. J Clin Med 2026 · PMID 41976918 · DOI 10.3390/jcm15072617
  6. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.. Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031
  7. The impact of proton pump inhibitor exposure on pneumonia: an updated meta-analysis based on randomized controlled trials.. Wu Z et al.. Front Pharmacol 2025 · PMID 41230098 · DOI 10.3389/fphar.2025.1713256

← Back to overview